CARB-X Pipeline - 2025-06-30

Aug 28, 2026

Upload by Connor

CARB-X portfolio and active pipeline overview, as of 6/30/25, organized by graduates and currently funded projects across therapeutics, preventatives, and diagnostics. The document lists product names, developers, lead candidates, development stages, and technical descriptors such as bacterial targets, spectrum of activity, syndromes, and verification steps. It distinguishes graduation-stage progress and highlights ongoing development pathways from feasibility to optimization and early clinical phases.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages3

Reading Time8 min

AccessFree to download

CARB-X Complete Portfolio (as of 6/30/25)

Graduates-Therapeutics

Graduates-Preventatives

Graduates-Diagnostics

Active Product Pipeline (as of 6/30/25)

Active-Therapeutics Projects

Active-Preventatives Projects

Active-Diagnostics Projects

|
CARB-X Complete Portfolio, as of 6/30/25
Since CARB-X was launched in July 2016 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | CARB-X GRADUATES-THERAPEUTICS | | | | | | | | | | | | Novelty* | | | | | | Development Stage | | | | | |
Product Developer & Graduation Date
Peptilogics 12/24 | Product
PLG0206: Direct-acting engineered peptides | Bacteria
Broad spectrum | New
Abx
Cls
•
•
•
• | New
Abx
Tgt | Non
trad
•
•
•
• | Hit-to-lead | Lead
Optimization | | Pre-Clinical | Phase 1 | | | | | | | | | | | | | | | | | | | | | | | | | | Trellis Bioscience 5/24
Clarametyx Biosciences 11/22 | TRL1068: Antibiofilm monoclonal antibody
CMTX-101: Antibiofilm Monoclonal Antibody | Broad spectrum
ESKAPE, MRSA | | •
•
• | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | GlaxoSmithKline 12/21 | GSK3882347: FimH Antagonist UTI | E. coli | | | | | | | | | | | | | | | | | | | | | | Entasis Tx. 12/20 | ETX0282CPDP: Oral Combination | Gram-negative pathogens | | | | | | | | | | Tetraphase 06/19 | TP-6076: Novel Fluorocycline | Acinetobacter, Enterobacteriaceae | | | | | | | | | | | | | | | | | | | | | | Iterum 03/19 | Sulopenem | Gram-negative activity | | | | | | | | | | | | | | | | | | | | | | Spero 03/18 | SPR741: Antibiotic Potentiator | Gram-negative activity | • | | • | | | | | | | | | | | | | | | | | | | Oppilotech 10/17 | LPS | Gram-negative pathogens | | | | | | | | | | CARB-X GRADUATES-PREVENTATIVES | | | | | | | | | | | | Novelty* | | | | | | Development Stage | | | | | |
Product Developer & Graduation Date
GlaxoSmithKline 06/25 | Product
GSK iNTS-TCV iNTS-typhoid conjugate vaccine | Bacteria
Salmonella enterica | Type
Vaccine | | | Hit-to-lead | Lead
Optimization | | Pre-Clinical | Phase 1 | | | | | | | | | | | | | | | | | | | | | | | | | | Seres 04/21 | SER-155: LBP Cocktail Preventative | Broad spectrum activity vs CRE/VRE | Microbiome | | | | | | | | | | | | | | | | | | | | | Vedanta 09/18 | VE303: LBP Cocktail Preventative | C.difficile | Microbiome | | | | | | | | | CARB-X GRADUATES-DIAGNOSTICS | | | | | | | | | | | | Development Stage | | | | | | | | | | | | Product Developer & Graduation Date | Product | Syndrome | Healthcare
Level | | | Feasibility | Optimization | | Develop
ment | Verification & Validation | | Pattern Bioscience 06/23 | Digital culture single cell biometric analysis | Lower respiratory tract infections | LIV | | | | | | | | | | | | | | | | | | | | | Helixbind 03/22 | Rapid/BSI, Automated culture-free | Bloodstream infections | LIV | | | | | | | | | Proteus 02/22 | Rapid POC Dx, Optical bacterial imaging | Lower respiratory tract infections | LIV | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Specific Diagnostics 03/20 | SPECIFAST REVEAL™, Colorimetric Sensor Array to detect VOCs | Bloodstream infections | LIV | | | | | | | | | | | | | | | | | | | | | T2 Biosystems 09/19 | Expanded bacteria and resistance panels for T2Dx | Bloodstream infections | LIV | | | | | | | | | | | | | | | | | | | | | *Note: Regarding CARB-X graduates, red bars represent Development Stage while in the CARB-X porfolio, and pink bars represent Development Stage progress after graduating from the CARB-X program. | | | | | | | | | | | | | | | | | | | | | | | | Active Product Pipeline, as of 6/30/25
Products currently funded and supported by CARB-X | | | | | | | | | | | | ACTIVE-THERAPEUTICS PROJECTS | | | | | | | | | | | | Product Developer
ArrePath

FAQs

How is the CARB-X content organized in the portfolio overview?

It is organized into a complete portfolio as of 6/30/25, including graduate listings for therapeutics, preventatives, and diagnostics, followed by an active product pipeline section covering currently funded projects.

What development-stage information does the document provide for CARB-X products?

For each product it records progress through stages such as feasibility, hit-to-lead, lead optimization, pre-clinical, and Phase 1, and it also indicates development-stage progress related to graduation.

What kinds of technical descriptors are included for therapeutics and diagnostics?

Therapeutics entries include targets and spectrum of activity (e.g., Gram-negative activity, ESKAPE, MRSA), while diagnostics entries describe the syndrome focus and diagnostic approach steps such as verification and validation.

Aug 28, 2026

Upload by Connor